First-in-human study of INCA32459, a LAG-3/PD-1 bsAb in advanced cancers
Автор: VJOncology
Загружено: 2026-02-10
Просмотров: 47
Описание:
Jesus Fuentes-Antras, MD, NEXT Oncology Madrid, Hospital Universitario Quirónsalud Madrid, Madrid, Spain, discusses the first-in-human Phase I study of INCA32459 (NCT05577182), a bispecific antibody (bsAb) targeting PD-1 and LAG-3 in patients with select advanced malignancies. INCA32459 demonstrated a manageable safety profile consistent with immune checkpoint inhibitors, linear pharmacokinetics, and evidence of T-cell activation. Early efficacy was observed, including complete and partial responses in heavily pretreated tumors. This interview took place at 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress in London, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
